- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1360614-48-7] Necrosulfonamide
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-100573 |
| Brand: | MCE |
| CAS: | 1360614-48-7 |
Overview
| MDL | MFCD02370191 |
|---|---|
| Molecular Weight | 461.47 |
| Molecular Formula | C18H15N5O6S2 |
| SMILES | O=C(NC1=CC=C(S(=O)(NC2=NC=CN=C2OC)=O)C=C1)/C=C/C3=CC=C([N+]([O-])=O)S3.[(E)] |
44 Publications Citing Use of MCE
- [1]Circulation. 2022 Nov 30.
- [2]Nat Commun. 2022 Nov 17;13(1):7031.
- [3]J Clin Invest. 2021 Nov 9;e151268.
- [4]Cell Death Differ. 2021 Apr;28(4):1222-1236.
- [5]Redox Biol. 2021, 101942.
- [6]Autophagy. 2021 Jul 20;1-19.
- [7]Theranostics. 2020 Jun 19;10(17):7710-7729.
- [8]Stroke. 2018 Oct;49(10):2473-2482.
- [9]J Invest Dermatol. 2021 Jul 6;S0022-202X(21)01416-0.
- [10]J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.
- [11]Cell Death Dis. 2023 Jan 12;14(1):22.
- [12]Cell Death Dis. 2021 Apr 30;12(5):426.
- [13]Cell Death Dis. 2020 Mar 13;11(3):183.
- [14]Transl Stroke Res. 2021 Dec;12(6):991-1017.
- [15]EBioMedicine. 2022 Oct;84:104258.
- [16]Am J Cancer Res. 2021 May 15;11(5):2062-2080.
- [17]Oxid Med Cell Longev. 04 Aug 2022.
- [18]Oxid Med Cell Longev. 19 Oct 2021.
- [19]FASEB J. 2022 Dec;36(12):e22625.
- [20]FASEB J. 2022 May;36(5):e22316.
- [21]J Inflamm Res. 2021 Jul 5;14:2955-2962.
- [22]Int J Biol Sci. 2022 Jun 21;18(10):4135-4150.
- [23]J Cell Sci. 2021 Dec 3;jcs.258910.
- [24]Int J Mol Sci. 2019 Nov 24;20(23):5896.
- [25]Cells. 2022, 11(22), 3580
- [26]Front Pharmacol. 2021 May 10;12:670224.
- [27]Front Pharmacol. 2019 Sep 3;10:968.
- [28]J Agric Food Chem. 2020 Feb 5;68(5):1326-1336.
- [29]J Agric Food Chem. 2019 Sep 25;67(38):10637-10645.
- [30]J Transl Med. 2022 Oct 2;20(1):444.
- [31]Front Cell Infect Microbiol. 2022 Feb 4;12:825824.
- [32]Cell Death Discov. 2022 Mar 12;8(1):112.
- [33]Cell Death Discov. 2022 Feb 2;8(1):44.
- [34]Mol Immunol. 2022 Dec 9;153:160-169.
- [35]Mol Immunol. 2022 Jul 6;149:94-106.
- [36]Arch Biochem Biophys. 2021 Aug 23;711:109015.
- [37]Front Physiol. 2019 Jan 15;9:1922.
- [38]Drug Des Devel Ther. 2019 Jul 2;13:2135-2144.
- [39]Transl Cancer Res. 2021 Dec;10(12):5307-5318.
- [40]SSRN. 26 Oct 2022.
- [41]Pharmacological Research-Modern Chinese Medicine. 29 August 2022, 100157.
- [42]Research Square Preprint. 2021 May.
- [43]Research Square Preprint. 2021 Jan.
- [44]bioRxiv. 2020 Dec 14.
Summary
Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL) . Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis [1] .
In Vitro
Necrosulfonamide specifically blocks necrosis downstream of RIP3 activation. Necrosulfonamide inhibits MLKL-mediated necrosis by blocking Its N-terminal CC domain function [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 28 mg/mL ( 60.68 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1670 mL | 10.8349 mL | 21.6699 mL |
| 5 mM | 0.4334 mL | 2.1670 mL | 4.3340 mL |
| 10 mM | 0.2167 mL | 1.0835 mL | 2.1670 mL |
-
1.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 10 mg/mL (21.67 mM); Suspended solution; Need ultrasonic
-
2.
Add each solvent one by one: 20% SBE-β-CD in saline
Solubility: 6.67 mg/mL (14.45 mM); Suspended solution; Need ultrasonic
-
3.
-
4.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic
-
5.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.